Back to search

Aristotle University Of Thessaloniki (AUTH)

Η επίδραση της σιμπουτραμίνης στην ορμονική και μεταβολική εικόνα παχύσαρκων γυναικών με το σύνδρομο πολυκυστικών ωοθηκών

Abstract

dc:description

This clinical study was a comparative, open-label, randomized, phase IV trial. The study was designed with the following aims: a) the effect of weight loss to hormonal, metabolic and anthropometric features in overweight and obese women with PCOS, b) if treatment with sibutramine plus hypocaloric diet (sibutramine group) is more favorable in weight loss and hormonal and metabolic features as well, compare with hypocaloric diet only (control group), in overweight and obese women with PCOS, c) the percentage of women with PCOS and BMI>27 kg/m² and metabolic syndrome and d) the effect of weight loss in the prevalence of metabolic syndrome, between the two study groups (sibutramine group vs. control group). 97 overweight and obese women (BMI>27 kg/m²) were studied. The diagnosis of PCOS was based to the diagnostic criteria of 2003 (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group). PCOS diagnosis is made when; at least, two out of the three following features are present: a) chronic oligo- or anovulation, b) biochemical or clinical hyperandrogenaemia, and c) polycystic ovarian morphology on the ultrasound scan. With this definition, four PCOS phenotypes can be discerned. 59 women (60.82%) were classified as phenotype Ia, with chronic oligo- or anovulation, biochemical hyperandrogenaemia and polycystic ovarian morphology on the ultrasound scan. Five women (5.15%) were classified as phenotype Ib, with chronic oligo- or anovulation, clinical hyperandrogenaemia and normal androgens level and polycystic ovarian morphology on the ultrasound scan. In addition, twenty women (20.62%) were classified as phenotype IIa, with chronic oligo- or anovulation and biochemical hyperandrogenaemia and normal ovarian morphology on the ultrasound scan. Four women (4.12%) were classified as phenotype IIb, with chronic oligo- or anovulation and clinical hyperandrogenaemia. Phenotypes Ia, Ib, IIa and IIb fulfill the diagnostic criteria of 1990 NHI (National Institutes of Health) - sponsored conference on PCOS as well. In phenotype IIIa, six women (6.19%) with normal ovulate menstrual cycles and biochemical hyperandrogenaemia and polycystic ovarian morphology on the ultrasound scan were classified. Finally, three women (3.09%) were classified as phenotype IV, with chronic oligo- or anovulation and polycystic ovarian morphology on the ultrasound scan, without biochemical or clinical hyperandrogenaemia. It is noteworthy, that phenotypes IIIa and IV are fulfill the PCOS diagnostic criteria of 2003 (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group). Before entering the run-in period, all women received advice regarding diet. Prescription of a written hypocaloric diet was given to all women. This hypocaloric diet was based on the individual basal metabolic rate, as defined by the Harris-Benedict’s equation adjusted for moderate physical activity, with a 600 Kcal daily deficient diet. All women were prescribed an energy-restricted diet containing 50% carbohydrate, 30% fat (10% saturated), and 20% protein. Entering the treatment period, all women were randomized in 2:1 ratio to sibutramine group vs. control group, respectively. Treatment period was lasting for six months. All women were monthly followed for weight loss. Measurements of weight, BMI, waist and hip circumferences, blood pressure, heart rate, adverse events, compliance with the study drug and any other change, were monthly reported as well. During three and six months study visit, all women were submitted to the baseline investigation, such as androgens level and lipid profile and oral glucose tolerance test with 75gr of glucose per os was performed as well. Pregnancy test was monthly collected in all women included in the study. During baseline and three and six month visits, blood samples from all women were collected. The following parameters were determined: Follicle stimulating hormone (FSH), Luteinizing hormone (LH), Prolactin (PRL), Total testosterone (Τ), Δ4-androstendione (Δ4-Α), Dehydro-epiandrosterone sulphate (DHEA-S), 17a-hydroxyprogesterone (17a-OH-Pg), Sex hormone binding globulin (SHBG), Glucose, Insulin, Thyroid stimulating hormone (TSH), Free thyroxin (FT4). In addition, full blood count and biochemical screening tests were collected as well. Based on the hormonal levels and glucose levels was calculated: a) the homeostasis model of insulin resistance assessment, HOMA-IR (insulin expressed as μU/ml x glucose expressed as mg/dl/405) and b) the Free Androgen Index (FAI): Testosterone (nmol/l)/SHBG (nmol/l), in order to evaluate the biologically active testosterone, as well as the grade of hyperandrogenaemia. FAI>5, indicates hyperandrogenaemia. Consequently, all women were investigated with an oral glucose tolerance test, with 75gr of glucose per os. Blood samples were collected at the baseline (time 0) and every 30 minutes for 2 hours. Glucose levels every 30 minutes and baseline insulin levels were measured. Finally, the ovarian morphology, via vaginal ultrasound scan, was examined. The following ultrasound scan’s parameters were calculated; a) the volume of each ovary (d₁ x d₂ x d₃ x 0,523). Ovary volume >10 cm³ was considered as increased volume and b) the number of small follicles with 2-9 mm diameter. Diagnosis of polycystic ovarian morphology was determined when the number of small follicles for each ovary was >11. The normality of distribution was checked for all variables with the Kolmogorov-Smirnov test. All variables were normally distributed. Statistical analysis was performed using the absolute values as well as the percentage change from baseline at 3 and 6 months of treatment. Percent changes from zero and the percent change’s difference between groups were evaluated with the Student t-test for independent samples. Comparisons of means between groups throughout the measurement time points were performed with repeated measures two-way analysis of variance (ANOVA). An analysis of covariance (ANCOVA) was employed to test the differences in FAI and glucose AUC. Body weight at each time point was used as covariate in the former analysis and body weight and total testosterone were the covariates in the latter analysis. The main study’s findings were: 1) The combination of sibutramine plus hypocaloric diet leads to significant higher weight loss (13.2 Kg, percentage 14.86%) compare with hypocaloric diet only (8.3 Kg, percentage 9.24%). 2) The significant weight loss observed in overweight and obese women with PCOS leads to favorable outcome in all metabolic risk factors that are associated with the syndrome, such as insulin resistance, dyslipidaemia and hyperandrogenaemia. 3) Reduction of the total testosterone level, FAI and triglycerides could be an additional explanation for the improvement of insulin resistance. Therefore, body weight reduction is the cornerstone and is the first step for the treatment of overweight and obese women with PCOS. 4) Initial body weight reduction more than 15% is associated with significant improvement of insulin resistance in overweight and obese women with PCOS. 5) PCOS and metabolic syndrome have common pathogenetic mechanisms that are related with obesity. Insulin resistance plays a significant role to these mechanisms. 6) Overweight and obese women with PCOS have significant higher incidence of metabolic syndrome compare with the general population. 7) The incidence of metabolic syndrome in women with PCOS depends on; a) the diagnostic criteria that are used for each syndrome definition, b) the BMI and c) the age of study population. 8) The risk for metabolic disturbances and for metabolic syndrome in women with PCOS is higher to women with hyperandrogenaemia and chronic oligo- or anovulation. Therefore, the categorization of PCOS’ phenotypes is essential for the clinical practice. 9) Incidence of metabolic syndrome is relative high to women with PCOS and BMI>27 kg/m² and age <30 years old. 10) Screening of women with PCOS includes extensive investigation for metabolic disturbances of the syndrome and an OGTT should be included in the initial investigation as well. 11) Implementation of aggressive treatment in women with PCOS and cardiovascular risk factors is recommended as well.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2010

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Florakis, Dimos
  • Φλωράκης, Δήμος

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/21986

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Florakis, Dimos; Φλωράκης, Δήμος. Η επίδραση της σιμπουτραμίνης στην ορμονική και μεταβολική εικόνα παχύσαρκων γυναικών με το σύνδρομο πολυκυστικών ωοθηκών. Aristotle University Of Thessaloniki (AUTH), 2010. http://hdl.handle.net/10442/hedi/21986